NCT05097742|Completed
Cognitive Impairments in Children With Epilepsy
Interest of Speech Therapy in Children With Epilepsy: What Impairments of Cognitive Functions?
Loading search results
Interest of Speech Therapy in Children With Epilepsy: What Impairments of Cognitive Functions?
Sponsor study identifier
observational
30
1 country
1
Study Start
October 15, 2021
Actual (reported)Primary Completion
February 1, 2022
Actual (reported)Study Completion
February 20, 2022
Actual (reported)Since the proportion of language and attentional difficulties in patients with epilepsy is recognized, both in the literature and in the clinical experience of practitioners, it is appropriate to propose a complete speech-language assessment of oral language and attention.This study investigates these impairments through the taking of specific tests. The general objective of this study is to observe possible oral language and attention disorders in children with epilepsy, by age and etiology of epilepsy. The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 20, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 15, 2021
Actual (reported)October 27, 2021
Actual (reported)October 28, 2021
Actual (reported)February 1, 2022
Actual (reported)February 20, 2022
Actual (reported)Score in the different tests assessing oral language
Test assessing oral language : * Oral naming of images * Oral designation of images * Morphosyntactic comprehension test * Syntactic production test The scores obtained in the various tests are organized into 7 classes: Class 1 = percentiles less than 7 : "pathological" zone Class 2 = 7 to 20 percentiles : "fragile" zone / "weak" zone Class 3 = 21 to 38 percentiles : "low standard" zone Class 4 = percentiles 39 to 62 : "median standard" zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : "higher standard" zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level.
day 1
Score in the different tests assessing attention
day 1
Children with epilepsy followed by Dr COLMARD at the Montpellier hospital and university center
Uh Montpellier
Montpellier, 34295, France
Maxime colmard, résident
UH MONTPELLIER
Moritz-Gasser Sylvie
UH MONTPELLIER
30 participants (actual enrollment reported by the registry).
First Submitted
October 27, 2021
First Posted
October 28, 2021
Study Start
October 15, 2021
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
February 1, 2022
Actual (reported)Study Completion
February 20, 2022
Actual (reported)Last Updated
April 12, 2022
Record last verified: 2022-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: